GNFTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	1 419.00
平均出来高	6 052.00
時価総額	173.41M
EPS	$0 ( 2024-04-11 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.63
ATR14	$0 (0.00%)

Genfit SA 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Genfit SA 財務諸表

Annual	2023
収益:	$28.57M
総利益:	$28.22M (98.81 %)
EPS:	$-0.580

FY	2023
収益:	$28.57M
総利益:	$28.22M (98.81 %)
EPS:	$-0.580

FY	2022
収益:	$20.20M
総利益:	$19.95M (98.77 %)
EPS:	$-0.480

FY	2021
収益:	$80.07M
総利益:	$0.00 (0.00 %)
EPS:	$1.510

Financial Reports:

No articles found.

Genfit SA

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.